What guidance did CeriBell's management provide for the next earnings period?

Did CeriBell beat or miss consensus estimates last quarter?

What factors drove the changes in CeriBell's revenue and profit?

What is the market's earnings forecast for CeriBell next quarter?

What were the key takeaways from CeriBell's earnings call?

What is CeriBell's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for CeriBell year over year?

What is CeriBell's gross profit margin?

- **Revenue Growth**: Q4 2025 revenue up 34% YoY to $24.8 million, full-year up 36% to $89.1 million
- **New Product Launches**: Neonatal/pediatric seizure detection FDA-cleared, targeting Q2 2026 launch; delirium algorithm FDA-cleared
- **Gross Margin Stability**: Mid-80s% expected in 2026 despite tariff headwinds
- **2026 Guidance**: $111-115 million revenue (25-29% YoY growth)
- **Key Risks**: Ongoing patent litigation with Natus (~$10M+ annual expenses), tariff policy uncertainty
- **Upcoming Catalysts**: Delirium pilot results (Q2 2026), LVO stroke monitoring clinical data


**【CEO Opening Remarks】**
- Q4 2025 revenue: $24.8 million (34% YoY growth), full-year revenue: $89.1 million (36% YoY growth). 
- Gross margins: 87% (Q4) and 88% (full-year), driven by disciplined cost management and manufacturing diversification.
- Active accounts: 647 (32 net new in Q4, 118全年), with 30% penetration in existing accounts.
- Neonatal and pediatric seizure detection FDA-cleared, targeting Q2 2026 commercial launch.
- Delirium algorithm FDA-cleared, LVO stroke monitoring receives Breakthrough Device Designation.

**【CFO Financial Commentary】**
- Q4 2025 financials:
  - Product revenue: $18.8 million (33% YoY)
  - Subscription revenue: $6.0 million (37% YoY)
  - Net loss: $13.5 million (-10% YoY)
- 2026 guidance: $111-115 million revenue (25-29% YoY growth)
- Cash position: $159.3 million as of Dec 31, 2025
- 2026 operating expenses: ~$170 million, with ~$12 million in R&D investments
- Gross margin expected to remain mid-80s despite tariff headwinds

**【Q&A Highlights】**
1. **2026 Growth Drivers**
   - Neonatal/pediatric launches: ~$20 million+ impact by end-2027
   - Delirium pilot: 30+ hospitals engaged, targeting Q4 2026 launch
   - System-level sales: 10+ hospital systems in pipeline
   - Utilization rate: 30% → 40%+ via departmental expansion

2. **Commercial Execution**
   - Neonatal sales cycle: 3-6 months (existing accounts), ~$10k+ incremental ASP
   - Delirium pricing: TBD, but leveraging existing salesforce
   - Tariff mitigation: Vietnam manufacturing line fully operational

3. **Risk & Litigation**
   - Natus patent case: ~$10 million+ annualized expenses, ITC decision expected Nov 2026
   - Tariff policy uncertainty: 2026 guidance excludes potential benefits

4. **Market Expansion**
   - VA system: 170+ hospitals, ~$10 million+ annualized revenue
   - International: ~$100 million+ TAM, early-stage discussions


CeriBell, Inc.(CBLL)-20260225-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 revenue up 31% YoY to $22.6 million; full-year guidance raised to $87-89 million. 
- **Market Penetration**: 615 active accounts (31 new Q3), targeting 200+ NICUs and 280 children's hospitals. 
- **Clinical Validation**: Pediatric Clarity algorithm shows 94.4% sensitivity in 645 patients; neonatal headcap cleared for preterm/term infants. 
- **Financial Strength**: $168.5 million cash; mid-80s gross margin expected for FY2026. 
- **Strategic Wins**: VA system partnership, neonatal product pipeline ($400M incremental market).

**【CEO Summary Section】**
- Q3 2025 revenue: $22.6 million (31% YoY growth), driven by 31 new active accounts (total 615). 
- Raised full-year 2025 guidance to $87-89 million (34% YoY growth). 
- Expanded into VA system with FedRAMP High Authorization; VA pilot shows intent for broader rollout. 
- Pediatric Clarity algorithm demonstrates 94.4% sensitivity, 93.1% specificity in 645 patients. 
- Neonatal headcap cleared for preterm and term infants; full neonatal Clarity launch planned for 2026. 
- Penetration: 10% of U.S. acute care hospitals, 30% within active accounts, 3% of total addressable market.

**【CFO Financial Commentary】**
- Product revenue: $17 million (28% YoY), Subscription: $5.6 million (44% YoY). 
- Gross margin: 88% (vs. 87% YoY), maintained despite tariffs via Vietnam manufacturing line. 
- Operating expenses: $34.6 million (39% YoY), driven by commercial expansion. 
- Cash reserves: $168.5 million; no plans to raise capital. 
- Q4 2025 gross margin expected to remain mid-80s; FY2026 guidance for mid-80s gross margin.

**【Q&A Highlights】**
- **2026 Outlook**: Management declines to provide 2026 guidance, but cites account additions and utilization as key drivers. 
- **Neonatal Launch**: 200 existing NICU accounts will adopt departmentally; 280 children's hospitals represent new account opportunity. 
- **Utilization Growth**: Tenured accounts growing via protocol adoption (stroke, cardiac arrest), departmental expansion (ED, step-down units). 
- **Competition**: Increased competitive activity in 2025, but Ceribell maintains momentum with superior clinical evidence and cybersecurity. 
- **VA Expansion**: First phase of VA rollout planned for next quarters, leveraging successful pilot results.

CeriBell, Inc. (CBLL) Q3 2025 Earnings Call Transcript

- **Revenue Beats Expectations**: Q2 2025 revenue up 38% YoY to $21.2M, with 26 new active accounts. Full-year guidance raised to $85-88M.
- **Gross Margin Expansion**: 88% gross margin in Q2, with Vietnam manufacturing ensuring mid-80%+ margins in 2026.
- **Pipeline Momentum**: Pediatric headcap pilot validates clinical value; neonatal algorithm development addresses $2B U.S. seizure detection market.
- **IP Defense**: Lawsuits against Natus Medical aim to protect 6 key EEG patents, signaling long-term competitive advantage.
- **Utilization Growth**: CAM-driven protocolization and health economic evidence reduce seasonal utilization volatility.


**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $21.2 million, up 38% YoY, driven by new account acquisitions and subscription growth. Active accounts increased by 26 to 584.
- **Commercial Strategy**: Focus on account acquisition and utilization expansion, with 55 territories targeted by end of August. CAMs (Clinical Account Managers) are driving protocolization and health economic evidence.
- **Pipeline Expansion**: FDA-cleared pediatric headcap pilot shows clinical value in NICU; delirium algorithm development aligns with unmet market need. Neonatal pilot validates hardware ease of use.
- **IP Defense**: Filed lawsuits against Natus Medical for alleged patent infringement of 6 key EEG technologies, seeking injunctions and damages.
- **Guidance Update**: Full-year 2025 revenue raised to $85-88 million (prev. $83-87M), reflecting 30-34% YoY growth.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Product ($15.9M, +38% YoY) and Subscription ($5.3M, +41% YoY). Gross margin improved to 88% (vs. 86% YoY).
- **Cost Structure**: Operating expenses rose 56% YoY to $33.6M, driven by commercial investments and IP litigation costs ($1.4M in Q2).
- **Supply Chain**: Established Vietnam manufacturing site to mitigate trade risks, with sufficient headband inventory for 2025. Target 2026 gross margin in mid-80% range.
- **Cash Position**: $177.4M in cash as of Q2, with confidence in achieving cash flow breakeven.

**【Q&A Key Highlights】**
- **Account Growth**: Territory manager additions (hired over past 12 months) expected to drive 2026 account growth. Q2 utilization trends align with seasonal ICU census patterns.
- **Gross Margin**: Vietnam production and China tariff relief enable mid-80%+ gross margins. Sequential Q2/Q1 expense control reflects sales meeting timing and IP litigation timing.
- **Utilization Drivers**: CAMs focus on departmental expansion, physician training, and protocolization. Neonatal and pediatric pilots demonstrate cost-saving potential (e.g., reduced ICU stays).
- **Competition**: Competitors' products lack clinical validation and cybersecurity (FedRAMP) differentiation. Ceribell maintains 3% market penetration of addressable U.S. patients.
- **Legal Costs**: Q2 G&A spike ($1.4M) reflects IP litigation prep. Ongoing costs expected to match Q2 levels through 2026.


CeriBell, Inc. (CBLL) Q2 2025 Earnings Call Transcript

- **Revenue Surge**: Q1 2025 revenue up 42% YoY to $20.5M, driven by new accounts and utilization.
- **Margin Strength**: 88% gross margin, sustained despite 55% OpEx growth for commercial expansion.
- **Govt Validation**: FedRAMP High authorization for 51 companies, only medical device maker.
- **Pediatric Breakthrough**: FDA-cleared Clarity for pediatric seizures, targeting 80% of pediatric ED visits at non-children’s hospitals.
- **Tariff Resilience**: Mid-80% gross margin maintained via reshoring plans and subscription revenue (97% margin, 25% of total).
- **Growth Catalysts**: 55 territory managers by mid-2025, 70%+ upside in existing accounts via ER/ICU/PICU expansion.


**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 total revenue of $20.5 million, up 42% YoY and 11% QoQ, driven by new account acquisitions and utilization in existing accounts.
- **Gross Margin**: 88% in Q1, up from 86% in Q1 2024, reflecting strong cost control and product mix.
- **Active Accounts**: 558 as of Q1, +29 QoQ, including first VA hospitals and FedRAMP High authorization for government use.
- **Product Development**: FDA clearance for pediatric Clarity algorithm, targeting 80% of pediatric ED visits at non-children’s hospitals.
- **Strategic Priorities**: Expand commercial team to 55 territory managers by mid-2025, invest in CAM team for utilization growth, and leverage AI for new indications like neonatal seizure detection.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Product ($15.6M, +41% YoY), Subscription ($4.9M, +45% YoY), with 97% gross margin on subscription revenue.
- **Operating Expenses**: $32.2M (+55% YoY) due to commercial expansion, R&D, and public company costs. Stock-based comp expected to add $50M to 2025 OpEx.
- **Full-Year Guidance**: Raised to $83-87M (vs. prior $81-85M), driven by Q1 execution and seasonal trends. Gross margin expected to remain mid-80% despite potential 145% tariffs on Chinese imports.
- **Cash Position**: $182.7M as of Q1, confident in achieving cash flow breakeven with current funds.

**【Q&A Highlights】**
- **Tariff Mitigation**: 10%+ gross margin impact if tariffs materialize, but plans to reshore manufacturing within quarters. 25% of revenue from tariff-exempt subscriptions.
- **Pediatric Clarity**: No 2025 contribution; limited pilot through 2025, full launch in 2026+. Addresses 3% of U.S. seizure market, 80% of pediatric ED visits at non-children’s hospitals.
- **Market Competition**: No meaningful competitors in rapid EEG; 70%+ upside in existing accounts via departmental expansion (ICU, ER, PICU).
- **Pricing Strategy**: Modest annual price increases, hospitals receptive due to cost savings and clinical value.
- **Contract Cycles**: Rolling 1-2 year contracts, no immediate tariff-driven price changes.
- **Clinical Adoption**: CAM team drives utilization via guideline education, protocol standardization, and departmental expansion (e.g., ER to ICU).


CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: Q4 2024 revenue up 41% YoY to $18.5 million, with full-year 2024 reaching $65.4 million (+45% YoY). 
- **Margin Strength**: Gross margin maintained at 88% (Q4) and 87% (full-year). 
- **Pipeline Momentum**: 
  - Delirium detection algorithm FDA submission in 2025. 
  - Stroke algorithm with 200+ patient data points collected. 
  - Neonatal seizure detection 510(k) in 2026. 
- **2025 Outlook**: Revenue guidance of $81–$85 million, supported by 55 territory managers by mid-2025 and $194 million cash runway. 
- **Tariff Mitigation**: 35% China tariffs offset by automation and scale, preserving mid-80% gross margin.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue of $18.5 million, up 41% YoY, driven by new account acquisitions and utilization. Full-year 2024 revenue reached $65.4 million, a 45% increase. Active accounts grew to 529, with 25 new additions in Q4.
- **Gross Margin**: Maintained strong margins at 88% (Q4) and 87% (full-year), reflecting manufacturing efficiency.
- **Strategic Priorities**: 
  - **Commercial Expansion**: Targeting 55 territory managers by mid-2025 to accelerate account acquisition. 
  - **Pipeline Development**: 
    - Neonatal seizure detection (510(k) submission in 2026). 
    - Delirium detection algorithm with FDA Breakthrough Device Designation (submission in 2025). 
    - Stroke detection algorithm with over 200 patient data points collected.
  - **Market Penetration**: 200,000+ patients treated since launch, with potential to reduce ICU days and improve outcomes.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: 
  - Product revenue: $14.1 million (+41% YoY). 
  - Subscription revenue: $4.4 million (+40% YoY). 
  - Net loss: $12.6 million, or $0.40 per share, due to public company expenses and R&D investments.
- **2025 Guidance**: 
  - Revenue: $81–$85 million (+24%–30% YoY). 
  - Gross margin: Mid to high 80%, despite 35% China tariffs. 
  - Operating Expenses: $15 million in stock-based compensation, with R&D investments accelerating pipeline development.
  - Cash Position: $194.4 million post-IPO, supporting long-term growth initiatives.

**【Q&A Key Highlights】**
- **Account Adds & Utilization**: Q4 2024 added 25 accounts ahead of expectations, with Q1 2025 launches aligning with Q4 trends. CAM team focuses on protocol integration to drive utilization in non-ICU settings.
- **Tariff Impact**: 35% China tariffs on headband components offset by automation and scale benefits, maintaining margin stability.
- **Pipeline Progress**: 
  - Delirium algorithm submission in 2025, targeting 50%–80% ICU patients. 
  - Stroke detection algorithm enrollment accelerating with 200+ patient data points. 
  - Neonatal algorithm testing underway for 2026 FDA submission.
  - VA hospital engagement showing strong interest in rapid EEG adoption.


Actual	-1.85	-0.4	-0.36	-0.38	-0.37	-0.36
Forecast	-0.3434	-0.318	-0.4072	-0.3971	-0.4142	-0.4121
Surprise	-438.73%	-25.79%	+11.59%	+4.31%	+10.67%	+12.64%

Actual	17.20M	18.53M	20.49M	21.20M	22.59M	24.78M
Forecast	16.93M	17.55M	19.26M	20.45M	21.77M	23.93M
Surprise	+1.59%	+5.59%	+6.39%	+3.65%	+3.76%	+3.58%

CBLL

CBLL fundamentals

CBLL Q4 2025 Earnings

Earnings Call

You can ask Aime

CBLL

CBLL fundamentals

CBLL Q4 2025 Earnings

Earnings Call

CBLL Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

CBLL Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

CBLL Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

CBLL Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

CBLL Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

You can ask Aime